Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arrowhead Pharmaceuticals Inc.

www.arrowheadpharma.com

Latest From Arrowhead Pharmaceuticals Inc.

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.

Business Strategies Companies

Finance Watch: IPOs Are In A Slump, But Already Public Companies Have Rallied

Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m. 

Financing Business Strategies

Roche Secures Dicerna RNAi Deal For Hepatitis B

Roche has paid $200m up front to get its hands on Dicerna’s RNAi-based drug for chronic hepatitis B in a deal that could be worth around $1.5bn.

Commercial Companies

GSK Opts In On Ionis’ Antisense Candidates For Hep B

The pharma is taking over a pair of Ionis candidates intended to address the underlying cause of HBV, possibly offering a curative therapy. It’s just the second HBV licensing agreement in 2019, after heavier deal flow in recent years.

Deals Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Arrowhead Research Corp.
  • InterActive Group Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arrowhead Pharmaceuticals Inc.
  • Senior Management
  • Christopher Anzalone, PhD, Pres. & CEO
    Ken Myszkowski, CFO
    James Hassard, Chief Commercial Officer
    Bruce Given, MD, COO
    Javier San Martin, MD, CMO
    Curt Bradshaw, PhD, CSO
  • Contact Info
  • Arrowhead Pharmaceuticals Inc.
    Phone: (626) 304-3400
    177 East Colorado Blvd.
    Ste. 700
    Pasadena, CA 91105
    USA
UsernamePublicRestriction

Register